Sunday, November 28th, 2021


A full text version of this article is available.
To access article obtain online access here or login
Subcutaneous Epstein-Barr Virus–Positive Diffuse Large B Cell Lymphoma Following Angioimmunoblastic T Cell Lymphoma and A Novel Treatment Modality: A Case Report
Authors:  Chao Guo, M.D., and Ming Gong, M.M.
  BACKGROUND: Sequential Epstein-Barr virus (EBV)–positive B cell lymphoma to the initial diagnosis of angioimmunoblastic T cell lymphoma (AITL) is very rare, the exact mechanism and standard therapy of which is still being explored. CASE: A 50-year-old man was admitted to our hospital in January 2014 with a three-week history of enlargement of multiple lymph nodes. His initial pathological evaluation indicated AILT. The reactivation of EBV was observed during the immunosuppression therapy for AITL, accompanied by onset of subcutaneous nodules proven to be EBV-positive diffuse large B cell lymphoma (DLBCL) based on the pathological findings of rebiopsy. The patient was successfully treated with chidamide, a histone deacetylase (HDAC) inhibitor, and rituximab.
The sufficient surveillance for serum EBV and repeat biopsy is necessary for patients with AITL, and this treatment modality may become an active option.
Keywords:  angioimmunoblastic T cell lymphoma, Epstein-Barr virus, HDAC inhibitor, non-Hodgkin lymphoma, peripheral T cell lymphoma
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from